Alterations of fibrin network structure mediated by dermatan sulfate

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 2, 2013, Pages 257-263

  Lauricella, Ana María ^a   Castañon, María Mercedes ^a   Kordich, Lucía C ^a   Quintana, Irene L ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Compaction; Dermatan sulfate; Fibrin formation; Fibrin network structure; Fibrinolysis

Indexed keywords

DERMATAN SULFATE; FIBRIN; FIBRINOGEN; UROKINASE;

ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; FIBRIN CLOT; HUMAN; IN VITRO STUDY; LYSIS; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; SCANNING ELECTRON MICROSCOPY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICOAGULANTS; CATTLE; DERMATAN SULFATE; FIBRIN; PROTEIN BINDING;

EID: 84877047209     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0804-9     Document Type: Article

References (29)

1. Casu B (1991) Structural features and binding properties of chondroitin sulfate, dermatan sulfate and heparan sulfate. Semin Thromb Hemost 17:9-14
2. Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B (1992) An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 89:321-326
3. Delorme MA, Saees N, Sevick A, Mitchell L, Berry L, Johnston M, Andrew M (1993) Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis. Blood 82:3380-3385
4. Rossi E, Duboscq C, Peragallo M, Kordich L (1997) Heparin cofactor II (HC II) and dermatan sulfate plasmatic levels in acute burnt patients. Thromb Haemost Suppl:435
5. Saito A, Munakata H (2007) Analysis of plasma proteins that binds to glycosaminoglycans. Biochim Biophys Acta 1770:241-246
6. Rau J, Mitchell J, Fortenberry Y, Church F (2011) Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost 37:339-348
7. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourão PA (2005) Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 1740:45-53
8. Han JH, Cote HCF, Tollefsen DM (1997) Inhibition of meizothrombin and meizothrombin(des F1) by heparin cofactor II. J Biol Chem 272:28660-28665
9. Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI (2001) Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276:20959-22065
10. Iacoviello L, D'Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB (1996) Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 76:1102-1107
11. Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B (1992) Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 68:637-641
12. Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. Pharmacoeconomics 19:57-68
13. Imberti D, Verso M, Silvestrini E, Taliani MR, Agnelli G (2003) Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost 1:2696-2697
14. Castañon MM, Gamba C, Kordich LC (2007) Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators. Thromb Res 120:745-752
15. Stirling Y, Woolf L, North W, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52:176-182
16. Wickström K, Edelstam G, Löwbeer C, Hansson L, Siebahn A (2004) Reference intervals for plasma levels of fibrinectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31-40
17. Delorme M, Burrows R, Ofosu F, Andrew M (1992) Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost 18:81-90
18. Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U (1996) Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 82:109-117
19. Giri TK, Tollefsen DM (2006) Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 107:2753-2758
20. Weisel JW, Litvinov RI (2008) The biochemical and physical process of fibrinolysis and effects of clots structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6:161-180
21. Lauricella AM, Quintana I, Castañon M, Sassetti B, Kordich L (2006) Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 17:181-186
22. Nair CH, Shats EA (1997) Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to crosslinking. Thromb Res 88:381-387
23. Colliec S, Fischer AM, Tapon-Bretaudiere J, Boisson C, Durand P, Jozefonvicz J (1991) Anticoagulant properties of a fucoidan fraction. Thromb Res 64:143-154
24. Weisel JW, Veklich Y, Collet JP, Francis CW (1999) Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 82:277-282
25. Wolberg AS, Gabriel DA, Hoffman M (2002) Analysing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 13:533-539
26. Jones M, Gabriel DA (1988) Influence of subendothelial basement membrane components on fibrin assembly. J Biol Chem 263:7043-7048
27. Litvinov RI, Yakovlev S, Tsurupa G, Gorkun OV, Medved L, Weisel JW (2007) Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 46:9133-9142
28. Weisel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5(Suppl. 1):116-124
29. Undas A, Ariëns R (2011) Fibrin clot structure and function. A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:88-99